EUCTR2013-001047-31-CZActive, not recruitingPhase 1
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 523
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Female
Inclusion Criteria
- •1. Subject has voluntarily signed and dated the informed consent form (ICF), approved by an Institutional Review Board/Ethics Committee (IRB/EC) prior to initiation of any study-specific procedures.
- •2. Subject has completed the 6-Month Treatment Period in pivotal study M12-671.
- •3. Subject must agree to use two forms of non-hormonal contraception (dual contraception) consistently during the Treatment and the Post-Treatment Follow-Up Periods (through Month 6).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 523
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. Pivotal study M12-671 Month 6 TVU or other diagnostic procedure shows clinically significant gynecological condition
- •2. Subject has BMD loss = 8% in the spine, femoral neck or total hip as specified per the algorithm for Management of Bone Loss at Month 6 of the Treatment Period in pivotal Study M12-671.
- •3. Subject met criteria for removal from therapy in pivotal Study M12-671.
- •4. Subject plans to become pregnant in the next 18 months.
- •5. Subject will be unable or unwilling to comply with study-related assessments and procedures
- •6. Subject has a newly diagnosed or clinically significant medical condition that requires intervention OR an unstable medical condition that makes the subject an unsuitable candidate for the study in the opinion of the investigator.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated PaiModerate to Severe Endometriosis Associated PainMedDRA version: 16.1Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 100000004872EUCTR2013-001047-31-ITAbbVie Deutschland GmbH & Co. KG495
Active, not recruiting
Phase 1
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated PaiModerate to Severe Endometriosis Associated PainMedDRA version: 19.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 100000004872EUCTR2013-001047-31-HUAbbVie Deutschland GmbH & Co. KG523
Active, not recruiting
Phase 1
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated PaiModerate to Severe Endometriosis Associated PainMedDRA version: 20.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 100000024185EUCTR2013-001047-31-ATAbbVie Deutschland GmbH & Co. KG523
Active, not recruiting
Phase 1
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated PaiModerate to Severe Endometriosis Associated PainMedDRA version: 17.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 100000004872EUCTR2013-001047-31-ESAbbVie Deutschland GmbH & Co. KG523
Active, not recruiting
Phase 1
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated PaiModerate to Severe Endometriosis Associated PainMedDRA version: 20.0 Level: LLT Classification code 10014788 Term: Endometriosis related pain System Organ Class: 100000024185EUCTR2013-001047-31-GBAbbVie Deutschland GmbH & Co. KG495